Index RUT
P/E -
EPS (ttm) -1.97
Insider Own 40.53%
Shs Outstand 54.87M
Perf Week -5.26%
Market Cap 931.35M
Forward P/E -
EPS next Y -1.90
Insider Trans -0.38%
Shs Float 40.07M
Perf Month 17.64%
Income -100.70M
PEG -
EPS next Q -0.42
Inst Own 60.13%
Short Float 17.29%
Perf Quarter 51.23%
Sales 0.00M
P/S -
EPS this Y 12.10%
Inst Trans -0.30%
Short Ratio 12.50
Perf Half Y 114.97%
Book/sh 4.08
P/B 3.38
EPS next Y -10.55%
ROA -39.88%
Short Interest 6.93M
Perf Year 192.23%
Cash/sh 3.09
P/C 4.47
EPS next 5Y -
ROE -45.11%
52W Range 4.69 - 16.65
Perf YTD 50.24%
Dividend Est. -
P/FCF -
EPS past 5Y -22.33%
ROI -43.49%
52W High -16.98%
Beta 1.03
Dividend TTM -
Quick Ratio 10.39
Sales past 5Y 0.00%
Gross Margin -
52W Low 194.72%
ATR (14) 0.89
Dividend Ex-Date -
Current Ratio 10.39
EPS Y/Y TTM 12.32%
Oper. Margin 0.00%
RSI (14) 51.85
Volatility 5.53% 7.37%
Employees 100
Debt/Eq 0.05
Sales Y/Y TTM -
Profit Margin -
Recom 1.12
Target Price 19.57
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q 4.97%
Payout -
Rel Volume 0.52
Prev Close 13.47
Sales Surprise -
EPS Surprise -2.62%
Sales Q/Q -
Earnings Mar 11 AMC
Avg Volume 554.30K
Price 13.82
SMA20 -5.22%
SMA50 10.46%
SMA200 55.36%
Trades
Volume 236,978
Change 2.65%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Initiated
Cantor Fitzgerald
Overweight
Sep-22-23 Initiated
Wedbush
Outperform
$8
Mar-23-23 Upgrade
H.C. Wainwright
Neutral → Buy
$16
Mar-21-23 Upgrade
Guggenheim
Neutral → Buy
$15
Mar-16-23 Upgrade
Oppenheimer
Perform → Outperform
$14
Jul-18-22 Resumed
Oppenheimer
Perform
Apr-04-22 Upgrade
Citigroup
Neutral → Buy
$7 → $10
Mar-25-22 Downgrade
H.C. Wainwright
Buy → Neutral
Mar-22-22 Downgrade
Oppenheimer
Outperform → Perform
Mar-22-22 Downgrade
Guggenheim
Buy → Neutral
Mar-22-22 Downgrade
Citigroup
Buy → Neutral
$22 → $7
Jul-06-21 Upgrade
Citigroup
Neutral → Buy
$34
Jan-25-21 Downgrade
Citigroup
Buy → Neutral
$34
Aug-13-20 Initiated
Robert W. Baird
Outperform
$45
Aug-06-20 Upgrade
Citigroup
Neutral → Buy
$35
Aug-03-20 Initiated
H.C. Wainwright
Buy
$52
May-19-20 Initiated
JP Morgan
Overweight
$40
May-19-20 Initiated
Jefferies
Buy
$40
May-19-20 Initiated
Guggenheim
Buy
$45
May-19-20 Initiated
Citigroup
Neutral
$35
Show Previous Ratings
Mar-26-24 09:55AM
Mar-12-24 09:01PM
Mar-11-24 04:05PM
Mar-08-24 05:01PM
Mar-06-24 04:30PM
04:30PM
Loading…
Mar-05-24 04:30PM
Mar-01-24 04:30PM
Feb-14-24 04:30PM
Feb-09-24 02:23AM
Feb-08-24 08:50AM
Feb-02-24 04:30PM
Feb-01-24 03:05PM
Jan-31-24 04:30PM
Jan-23-24 08:50AM
Jan-22-24 08:30AM
12:31PM
Loading…
Jan-09-24 12:31PM
Jan-08-24 08:30AM
Jan-02-24 04:30PM
Dec-11-23 12:00PM
Dec-05-23 09:11AM
Dec-01-23 04:30PM
Nov-09-23 04:30PM
Nov-06-23 05:22PM
04:10PM
Nov-03-23 04:30PM
Nov-02-23 09:00AM
Oct-21-23 07:30AM
Oct-17-23 04:30PM
Oct-16-23 12:00PM
Oct-06-23 04:30PM
04:30PM
Loading…
Sep-20-23 04:30PM
Sep-01-23 04:30PM
Aug-30-23 04:30PM
Aug-10-23 04:05PM
Aug-04-23 04:30PM
Jun-26-23 01:04PM
08:30AM
Jun-02-23 04:15PM
May-31-23 04:10PM
May-28-23 09:28AM
May-08-23 04:05PM
May-05-23 04:15PM
Apr-25-23 04:30PM
06:35AM
Apr-18-23 04:15PM
Mar-31-23 08:40AM
Mar-29-23 07:53PM
Mar-16-23 04:05PM
03:10AM
Mar-14-23 04:30PM
Mar-06-23 04:15PM
Feb-03-23 04:30PM
Feb-01-23 04:30PM
04:25PM
Jan-27-23 08:41AM
Jan-09-23 08:00AM
Jan-03-23 04:30PM
Dec-22-22 11:35AM
08:38AM
07:54AM
Dec-21-22 05:48PM
Dec-19-22 08:13AM
Dec-13-22 08:00AM
Nov-08-22 04:10PM
Nov-07-22 04:05PM
Nov-03-22 09:00AM
Oct-22-22 08:36AM
Oct-21-22 12:06PM
Oct-14-22 09:37AM
Oct-13-22 12:51PM
Oct-07-22 04:30PM
10:01AM
Sep-28-22 01:47PM
Sep-22-22 10:50AM
Sep-21-22 06:32PM
Sep-13-22 03:45PM
08:44AM
Sep-07-22 01:31PM
Sep-05-22 10:21AM
Sep-01-22 04:15PM
10:17AM
Aug-25-22 11:53AM
11:52AM
Aug-23-22 01:53PM
Aug-20-22 08:28AM
Aug-16-22 10:09AM
Aug-11-22 04:05PM
Jul-11-22 11:00AM
Jun-02-22 04:10PM
May-17-22 04:10PM
May-15-22 08:06AM
Apr-12-22 04:05PM
Mar-31-22 08:33AM
Mar-28-22 04:40PM
Mar-26-22 01:54PM
Mar-23-22 11:40AM
Mar-22-22 11:51AM
09:26AM
Mar-21-22 04:00PM
Mar-17-22 04:30PM
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Chacko Jacob PRESIDENT AND CEO Mar 06 '24 Sale 16.21 40,000 648,380 728,544 Mar 08 04:20 PM Chacko Jacob PRESIDENT AND CEO Feb 07 '24 Sale 12.29 26,042 320,186 768,544 Feb 08 08:01 PM Chacko Jacob PRESIDENT AND CEO Feb 06 '24 Sale 12.12 13,958 169,160 794,586 Feb 08 08:01 PM Multani Pratik S Chief Medical Officer Dec 15 '23 Option Exercise 0.00 14,042 0 29,091 Dec 19 07:42 PM Chacko Jacob President and CEO Dec 15 '23 Option Exercise 0.00 38,667 0 823,083 Dec 19 07:39 PM Chacko Jacob President and CEO Dec 15 '23 Sale 8.58 14,539 124,813 808,544 Dec 19 07:39 PM Multani Pratik S Chief Medical Officer Dec 15 '23 Sale 8.59 5,282 45,351 23,809 Dec 19 07:42 PM Piscitelli Dominic Chief Financial Officer Dec 15 '23 Sale 8.58 5,282 45,338 83,809 Dec 19 07:40 PM Chacko Jacob President and CEO Jul 11 '23 Sale 8.01 5,156 41,287 780,652 Jul 11 09:28 PM Chacko Jacob President and CEO Jul 10 '23 Sale 8.01 10,508 84,212 785,808 Jul 11 09:28 PM Chacko Jacob President and CEO Jul 05 '23 Sale 8.01 4,336 34,711 796,316 Jul 07 04:35 PM Chacko Jacob President and CEO Jun 26 '23 Sale 8.03 20,000 160,562 800,652 Jun 28 07:18 PM
Index RUT
P/E -
EPS (ttm) -3.05
Insider Own 12.10%
Shs Outstand 34.40M
Perf Week 4.11%
Market Cap 308.33M
Forward P/E -
EPS next Y -3.10
Insider Trans -0.18%
Shs Float 30.59M
Perf Month 2.31%
Income -116.80M
PEG -
EPS next Q -0.81
Inst Own 90.67%
Short Float 10.78%
Perf Quarter -64.39%
Sales 0.00M
P/S -
EPS this Y -9.23%
Inst Trans -1.64%
Short Ratio 2.65
Perf Half Y -47.88%
Book/sh 4.27
P/B 2.07
EPS next Y 6.83%
ROA -53.15%
Short Interest 3.30M
Perf Year -50.42%
Cash/sh 4.56
P/C 1.94
EPS next 5Y -
ROE -59.56%
52W Range 6.86 - 27.35
Perf YTD -64.35%
Dividend Est. -
P/FCF -
EPS past 5Y -12.39%
ROI -77.10%
52W High -67.61%
Beta 0.47
Dividend TTM -
Quick Ratio 7.41
Sales past 5Y -36.87%
Gross Margin -243.23%
52W Low 29.15%
ATR (14) 0.87
Dividend Ex-Date -
Current Ratio 7.41
EPS Y/Y TTM -18.00%
Oper. Margin 0.00%
RSI (14) 36.52
Volatility 5.27% 6.98%
Employees 131
Debt/Eq 0.05
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.92
Target Price 22.00
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q -25.08%
Payout -
Rel Volume 0.22
Prev Close 8.93
Sales Surprise -
EPS Surprise 6.90%
Sales Q/Q -
Earnings Mar 07 BMO
Avg Volume 1.25M
Price 8.86
SMA20 3.01%
SMA50 -45.37%
SMA200 -50.75%
Trades
Volume 227,247
Change -0.78%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-22-24 Downgrade
UBS
Buy → Neutral
$61 → $10
Feb-21-24 Downgrade
Leerink Partners
Outperform → Market Perform
$42 → $10
Feb-21-24 Downgrade
JP Morgan
Overweight → Neutral
$35 → $15
Feb-21-24 Downgrade
H.C. Wainwright
Buy → Neutral
Feb-20-24 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Feb-16-24 Initiated
Evercore ISI
Outperform
Feb-15-24 Initiated
Wolfe Research
Outperform
$39
Sep-14-23 Initiated
Berenberg
Buy
$34
Aug-09-23 Initiated
Stifel
Buy
$40
Jun-15-23 Initiated
Barclays
Overweight
$35
Jan-04-23 Initiated
Guggenheim
Buy
$55
Dec-01-22 Initiated
Goldman
Buy
$27
Sep-21-22 Initiated
CapitalOne
Overweight
$48
May-24-22 Resumed
Cantor Fitzgerald
Overweight
$58 → $44
Dec-09-21 Initiated
JP Morgan
Overweight
$61
Aug-12-21 Initiated
SVB Leerink
Outperform
$49
Jun-21-21 Initiated
Piper Sandler
Overweight
$61
Jun-01-20 Initiated
H.C. Wainwright
Buy
$40
May-19-20 Initiated
Cantor Fitzgerald
Overweight
$37
Apr-13-20 Initiated
ROTH Capital
Buy
$38
Show Previous Ratings
Mar-22-24 05:39AM
Mar-07-24 02:52PM
08:36AM
08:00AM
Mar-05-24 04:30PM
04:03PM
Loading…
Feb-20-24 04:03PM
(Investor's Business Daily) -73.55%
11:22AM
07:58AM
07:39AM
07:30AM
07:17AM
Feb-13-24 08:00AM
Jan-31-24 08:00AM
Jan-02-24 08:00AM
Nov-27-23 08:00AM
07:41PM
Loading…
Nov-14-23 07:41PM
Nov-13-23 08:00AM
Nov-03-23 12:00PM
Nov-01-23 04:05PM
Oct-18-23 09:00AM
Sep-27-23 09:24PM
Sep-14-23 09:44AM
Aug-30-23 04:05PM
Aug-16-23 09:55AM
Aug-11-23 08:00AM
Aug-09-23 10:26AM
Aug-08-23 06:03AM
Jun-07-23 08:00AM
May-25-23 05:00PM
May-11-23 08:00AM
08:00AM
Loading…
May-03-23 08:00AM
Apr-26-23 04:19PM
Mar-29-23 08:00AM
Mar-21-23 08:50AM
Mar-14-23 08:00AM
Mar-02-23 10:00AM
Feb-28-23 08:00AM
Feb-27-23 09:55AM
Feb-23-23 08:50AM
Feb-22-23 06:31AM
Feb-16-23 04:02AM
Feb-10-23 09:55AM
Feb-07-23 08:00AM
Jan-31-23 05:43PM
Jan-25-23 08:50AM
Jan-03-23 08:00AM
Dec-30-22 09:55AM
Dec-17-22 08:56AM
Dec-08-22 06:30AM
Nov-30-22 07:05PM
Nov-22-22 08:46AM
Nov-17-22 09:38PM
04:24PM
09:55AM
Nov-12-22 07:42AM
Nov-10-22 09:15AM
08:00AM
Nov-09-22 08:00AM
Oct-12-22 07:50AM
Sep-28-22 08:00AM
Sep-23-22 12:00PM
09:55AM
Sep-15-22 06:17AM
Sep-01-22 09:55AM
Aug-31-22 08:00AM
Aug-16-22 09:55AM
Aug-11-22 09:15AM
08:00AM
Jul-10-22 09:37AM
Jun-20-22 09:25AM
May-25-22 03:01PM
08:00AM
May-23-22 08:00AM
May-11-22 09:15AM
08:00AM
May-09-22 05:15PM
May-05-22 09:25AM
May-04-22 08:00AM
Apr-11-22 08:29AM
Mar-28-22 08:00AM
Mar-10-22 08:00AM
Mar-01-22 11:05AM
Feb-24-22 10:35AM
Feb-09-22 08:00AM
Feb-08-22 01:38PM
Jan-04-22 08:00AM
Nov-29-21 03:04PM
Nov-10-21 06:05PM
04:05PM
Nov-09-21 04:01PM
Nov-08-21 03:00PM
08:00AM
Oct-29-21 09:33AM
Oct-25-21 04:10PM
Oct-18-21 08:00AM
Sep-30-21 09:15AM
Sep-23-21 11:15AM
Sep-20-21 08:00AM
08:00AM
Sep-10-21 04:59PM
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Brockstedt Dirk G. CHIEF SCIENTIFIC OFFICER Jan 05 '24 Sale 22.78 898 20,456 27,820 Jan 08 05:50 PM Brockstedt Dirk G. Chief Scientific Officer Dec 29 '23 Option Exercise 6.18 8,000 49,440 27,070 Jan 02 04:29 PM HO WILLIAM Chief Medical Officer Dec 21 '23 Sale 21.68 2,500 54,200 15,020 Dec 22 02:31 PM HO WILLIAM Chief Medical Officer Nov 28 '23 Sale 13.72 1,500 20,580 17,520 Nov 29 02:29 PM HO WILLIAM Chief Medical Officer Oct 03 '23 Sale 15.77 2,500 39,425 18,789 Oct 04 06:29 PM HO WILLIAM Chief Medical Officer Aug 18 '23 Sale 18.92 2,500 47,300 21,289 Aug 22 12:19 PM HO WILLIAM Chief Medical Officer Jul 28 '23 Option Exercise 12.00 460 5,520 23,789 Aug 03 02:34 PM HO WILLIAM Chief Medical Officer Jun 23 '23 Option Exercise 12.00 920 11,040 23,329 Jun 27 12:14 PM HO WILLIAM Chief Medical Officer Apr 19 '23 Sale 18.88 5,000 94,400 20,992 Apr 20 02:17 PM HO WILLIAM Chief Medical Officer Apr 13 '23 Option Exercise 12.00 460 5,520 22,381 Apr 14 06:25 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite